https://www.selleckchem.com/pr....oducts/avacopan-ccx1
6% ( = 0.057 and 35.9% ( = 0.025 during years 1-5. In patients with the least (bottom quartile) most (top quartile) atrophy during years 1-2, risk of CDMS conversion was reduced by 58% (CGM; = 0.0024) and 58% (WB; = 0.0028) during years 1-2, and 42% (CGM; = 0.0138) and 29% (WB; = 0.1912) during years 1-5. These findings support the clinical relevance of CGM and WB atrophy and early intervention with teriflunomide in CIS. These findings support the clinical relevance of CGM and WB atrophy and early intervention with teriflun
Like
Comment
Share
